Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Resverlogix Corp (RVX.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 253,444
  • Shares Outstanding, K 209,154
  • Annual Sales, $ 0 K
  • Annual Income, $ -162,798 K
  • 60-Month Beta 0.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.87
  • Most Recent Earnings -0.48 on 10/31/19
  • Next Earnings Date 01/23/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.00 +21.00%
on 12/18/19
1.42 -14.79%
on 01/13/20
+0.14 (+13.08%)
since 12/17/19
3-Month
0.94 +28.72%
on 10/28/19
1.94 -37.63%
on 11/11/19
-0.27 (-18.24%)
since 10/17/19
52-Week
0.35 +245.71%
on 09/30/19
4.94 -75.51%
on 05/08/19
-2.04 (-62.77%)
since 01/17/19

Most Recent Stories

More News
CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

In a release issued earlier today under the same headline by Resverlogix Corp. (TSX: RVX), please note that the subheadline should read "BETonMACE Results Show 57% Hazard Reduction in Primary MACE for...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today additional highly significant findings and clear synergy when apabetalone is combined with anti-diabetic therapies,...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix Appoints Dicky To to its Board of Directors

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that Mr. Dicky To has been appointed to the Company's Board of Directors. His appointment is effective as of December 19, 2019....

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix Announces Change to its Board of Directors

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today.

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) reminds stakeholders that the Company will hold a conference call and webcast on December 6 at 8:30 am ET to supplement the presentation of...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix Announces Warrant Exercise Incentive Program

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces a warrant exercise incentive program ("Incentive Program") designed to encourage the early exercise of 15,593,428 warrants to purchase...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders

Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. A total of 66,053,596 shares (approximately 31.54% of...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the "Debenture") to a wholly-owned...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)
Resverlogix to Host BETonMACE Webcast and Conference Call

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected to be announced on September 30, 2019, the company plans to hold...

RVXCF : 0.8989 (-3.34%)
RVX.TO : 1.21 (+1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar